• About us
• Contact

Advertisement

Product › Details

proteasome inhibitor

	Next higher product group	cancer drug
	Status	0202-06-11 development existent
	Organisation	Millennium Pharmaceuticals Inc.
	Group	Takeda (Group)

Record changed: 2023-07-10

Advertisement

More documents for cancer drug

• [1] Tempus AI, Inc.. (9/26/24). "Press Release: Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-world Datasets and Biological Model Systems in Oncology Research and Development". Chicago, IL....
• [2] Adcendo ApS. (8/20/24). "Press Release: Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor". Copenhagen & Shanghai....
• [3] BioNTech SE. (8/19/24). "Press Release: Lift of Partial Clinical Hold for BNT326/YL202"....
• [4] AGC Biologics. (8/7/24). "Press Release: NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines"....
• [5] Shenzhen Synthetica Pioneering Co., Ltd.. (7/30/24). "Press Release: Synthetica Pioneering Closes a Series A Funding Round to Support Development of Oncolytic Bacterial Therapy for Solid Tumors". Shenzhen....
• [6] Full-Life Technologies. (7/17/24). "Press Release: Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors". Heidelberg & Seoul....
• [7] Scorpion Therapeutics, Inc.. (7/16/24). "Press Release: Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline". Boston, MA....
• [8] Sotio Biotech a.s.. (7/16/24). "Press Release: Sotio Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline". Prague & Beijing....
• [9] Catalym GmbH. (7/16/24). "Press Release: Catalym Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab". Munich....
• [10] Ipsen S.A.. (7/11/24). "Press Release: Ipsen and Foreseen Biotechnology Announce Exclusive Global Licensing Agreement for Antibody-Drug Conjugate with First-in-Class Potential". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.